[HTML][HTML] EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of …
Objectives To assess the ability of different technology platforms to detect epidermal growth
factor receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …
factor receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …
[PDF][PDF] EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of …
KS Thress, R Brant, TH Carr, S Dearden… - Lung …, 2015 - scholar.archive.org
abstract Objectives: To assess the ability of different technology platforms to detect
epidermal growth factor receptor (EGFR) mutations, including T790M, from circulating tumor …
epidermal growth factor receptor (EGFR) mutations, including T790M, from circulating tumor …
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
KS Thress, R Brant, TH Carr… - Lung cancer …, 2015 - pubmed.ncbi.nlm.nih.gov
Objectives To assess the ability of different technology platforms to detect epidermal growth
factor receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …
factor receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
KS Thress, R Brant, TH Carr, S Dearden… - Lung Cancer …, 2015 - europepmc.org
Objectives To assess the ability of different technology platforms to detect epidermal growth
factor receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …
factor receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …
[引用][C] EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of …
KS Thress, R Brant, TH Carr, S Dearden, S Jenkins… - Lung Cancer, 2015 - cir.nii.ac.jp
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison
of leading technologies to support the clinical development of AZD9291 | CiNii Research CiNii …
of leading technologies to support the clinical development of AZD9291 | CiNii Research CiNii …
[PDF][PDF] EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of …
KS Thress, R Brant, TH Carr, S Dearden, S Jenkins… - Lung …, 2015 - researchgate.net
abstract Objectives: To assess the ability of different technology platforms to detect
epidermal growth factor receptor (EGFR) mutations, including T790M, from circulating tumor …
epidermal growth factor receptor (EGFR) mutations, including T790M, from circulating tumor …
[PDF][PDF] EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of …
KS Thressa, R Brantb, TH Carrb, S Deardenc… - 2015 - cyberleninka.org
Objectives: To assess the ability of different technology platforms to detect epidermal growth
factor receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …
factor receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …
[PDF][PDF] EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of …
KS Thress, R Brant, TH Carr, S Dearden, S Jenkins… - Lung Cancer, 2015 - core.ac.uk
abstract Objectives: To assess the ability of different technology platforms to detect
epidermal growth factor receptor (EGFR) mutations, including T790M, from circulating tumor …
epidermal growth factor receptor (EGFR) mutations, including T790M, from circulating tumor …
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
KS Thress, R Brant, TH Carr, S Dearden, S Jenkins… - Lung Cancer, 2015 - infona.pl
To assess the ability of different technology platforms to detect epidermal growth factor
receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …
receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
KS Thress, R Brant, TH Carr, S Dearden… - Lung …, 2015 - lungcancerjournal.info
Objectives To assess the ability of different technology platforms to detect epidermal growth
factor receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …
factor receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …